Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen Planned Acquisition Of KAI Would Bring In Replacement For Sensipar

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen will get KAI’s late-stage-ready asset for a small upfront price and gives itself a logical line extension to its chronic kidney disease drug Sensipar.

You may also be interested in...



Amgen Gets Parsabiv CRL, Gives No Clues As To Why

FDA issued a complete response letter for the Sensipar follow-on, and Amgen declined to provide any details about the reason why or timeline for resubmission.

Amgen Files NDA For I.V. Rival To Sensipar

The calcimimetic etelcalcetide could be administered intravenously following dialysis sessions for chronic kidney disease patients with secondary hyperparathyroidism, eliminating the high pill burden associated with Sensipar.

Amgen’s KAI Deal Pays Off With Positive Phase III Trial Of Sensipar Successor

Drug acquired for $315 million in cash from KAI in 2012 – AMG 416 – hits all primary and secondary endpoints in first pivotal study of hyperparathyroidism in dialysis patients; two other trials have yet to report.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel